CARB-X funds VenatoRx Pharmaceuticals to support the development of a new class of oral antibiotics to treat multi-drug-resistant gonorrhea
November 25, 2019
VenatoRx Pharmaceuticals Names Joseph C. Larsen, Ph.D. Vice President, Strategic Portfolio Development
September 04, 2019
ASM Microbe 2019
June 23, 2019
SUNDAY - AAR-719 - Rescue of Ceftibuten Activity by the Oral β-Lactamase Inhibitor VNRX-7145 against Enterobacteriaceae Expressing Class A, C and/or D β-Lactamases
SUNDAY - AAR-720 - The Orally Bioavailable Beta-Lactamase Inhibitor VNRX-7145 Restores Bactericidal Activity of Ceftibuten against Enterobacteriaceae Expressing Ambler Class A, C, and/or D Enzymes
SUNDAY - AAR-721 - In Vitro Activity of Ceftibuten in Combination with VNRX-7145 and Comparators against 1,066 UTI Isolates Non-Susceptible to Amoxicillin-Clavulanate and Levofloxacin
SUNDAY - AAR-722 - Antimicrobial Activity of Cefepime in Combination with VNRX-5133 against a Global 2018 Surveillance Collection of Pseudomonas aeruginosa
SUNDAY - AAR-723 - Synergy/Antagonism of Ceftibuten/VNRX-7145 in Combination with Other Commonly Used Antimicrobial Agents in Gram-Negative Aerobic Bacteria, Anaerobic Bacteria, and Yeast
SUNDAY - AAR-724 - In Vitro Permeability and Metabolic Biotransformation of Oral Beta-Lactamase Inhibitor VNRX-7145 across Species
SUNDAY - AAR-726 - Efficacy of Ceftibuten + VNRX-7145 a Novel Beta-Lactamase Inhibitor against ESBL E. coli Strains in a Murine UTI Model Comparing a Commercially Prepared Dried MIC Susceptibility System to the CLSI/ISO Broth Microdilution Method for Ceftibuten-Clavulanic Acid Using Gram-Negative Non-Fastidious Organisms
SUNDAY - AAR-727 - Assessment of the In Vivo Pharmacodynamic Profile of Ceftibuten (CTB)/VNRX-7145 Combination against Serine β-Lactamase-Producing Enterobacteriaceae (SBL-EB) in the Neutropenic Murine Thigh Infection Model
SUNDAY - AAR-728 - Oral Bioavailability of Novel Beta-Lactamase Inhibitor VNRX-7145 in Rats, Dogs and Non-Human Primates
SUNDAY - CPHM-860 - Impact of Variations in Susceptibility Testing Parameters on the In Vitro Activity of Ceftibuten in Combination with VNRX-7145 ECCMID 2019
April 13 - 16, 2019
#O1061— Pharmacodynamics of VNRX-5133 in combination with cefepime studied in an in vitro model of infection.
#O1064 — In vivo pharmacodynamic profile of cefepime in combination with VNRX-5133 against serine beta-lactamase-producing Gram-negative bacteria in the neutropenic murine thigh infection model.
#P1175 — Antimicrobial activity of cefepime in combination with VNRX-5133 against a global 2018 surveillance collection of clinical isolates.
#P1176 — Antimicrobial activity of cefepime in combination with VNRX-5133 against a collection of beta-lactamase-producing Enterobacteriaceae.
#P1177 — Activity of cefepime/VNRX-5133 and comparators against an Italian nationwide collection of Pseudomonas aeruginosa from respiratory and bloodstream infections.
#P1178 — VNRX-5133 maintains potent inhibitory activity in engineered NDM-1 variants with increased cefepime hydrolytic efficiency.
#P1179 — Evaluation of the in vitro activity of cefepime plus VNRX-5133 and comparative agents against carbapenem-resistant Enterobacteriaceae.
#P1180 — In vitro activity of the orally available ceftibuten/VNRX-7145 combination against a challenge set of Enterobacteriaceae pathogens carrying molecularly characterised beta-lactamase genes.
#P1181 — Selection of ceftibuten as the partner antibiotic for the oral beta-lactamase inhibitor VNRX-7145.
#P1182 — Ceftibuten/VNRX-7145, an orally bioavailable beta-lactam/beta-lactamase inhibitor combination active against serine-beta-lactamase producing Enterobacteriaceae.
#P1183 — Oral ceftibuten/VNRX-7145 shows equivalent activity in vitro to IV therapeutics against MDR Enterobacteriaceae.
ID Week 2018
October 3 - 7, 2018
Poster 1360 – Antimicrobial Activity of Cefepime in Combination with VNRX-5133 Against a Global Collection of Enterobacteriaceae Including Resistant Phenotypes.
Poster 1370 – Cefepime/VNRX-5133 Broad-Spectrum Activity is Maintained against Emerging KPC- and PDC-Variants in Multidrug Resistant K. pneumoniae and P. aeruginosa.
Poster 1395 – Defining the Magnitude of AUC:MIC Driver for Efficacy of the beta-lactamase Inhibitor VNRX-5133 when combined with Cefepime against KPC- and VIM/NDM-producing Enterobacteriaceae and P. aeruginosa.
Poster 1401 – A Randomized, Double-blind, Placebo-controlled Study of the Safety and Pharmacokinetics of Single and Repeat Doses of VNRX-5133 in Healthy Subjects.
Poster 1405 – Efficacy of the Human-Simulated Regimen (HSR) of Cefepime (FEP)/VNRX-5133 Combination against Serine beta-lactamase-Producing Gram-negative Bacteria in the Neutropenic Murine Thigh Infection Model.
ASM Microbe 2018
June 7 - 11, 2018
FRIDAY 226 — Development of CLSI MIC and disk diffusion quality control ranges for Cefepime/VNRX-5133
FRIDAY 609 — In vitro activity of cefepime in combination with VNRX-5133 against gram-negative UTI isolates.
FRIDAY 610 — Cefepime/VNRX-5133 retains potent activity against KPC variants responsible for recent clinical treatment failures of Ceftazidime/Avibactam in Klebsiella Pneumoniae
FRIDAY 611 — Evaluation of the Impact of Variation in Standard Testing Parameters on the Activity of Cefepime in Combination with VNRX-5133
FRIDAY 612 — Efficacy of cefepime combined with VNRX-5133, a novel broad-spectrum β-lactamase inhibitor, against a cephalosporin-resistant ESBL E. coli in a murine UTI model
April 21 - 24, 2018
#O0575 — Pharmacodynamics of the novel broad-spectrum beta-lactamase inhibitor VNRX-5133 in combination with cefepime in neutropenic female CD-1 mice with experimental pneumonia.
#O0600 — Efficacy of cefepime / VNRX-5133, a novel beta-lactamase inhibitor combination, against cephalosporin-resistant, ESBL-producing K. pneumoniae in a murine lung-infection model.
#O0603 — Structural basis for serine- and metallo-beta-lactamase inhibition by VNRX-5133, a new beta-lactamase inhibitor (BLI) in clinical development.
#O0606 — Kinetic mechanism and parameters of inhibition of serine KPC-2, CTX-M15, p99 AmpC and metallo VIM-2 by the broad-spectrum beta-lactamase inhibitor VNRX-5133.
#P1536 — Potentiation of cefepime by the boronate VNRX-5133 versus gram-negative bacteria with known beta-lactamases.
#P1537 — Pharmacokinetics-pharmacodynamics (PK-PD) of VNRX-5133, a broad-spectrum novel beta-lactamase inhibitor (BS-BLI), in combination with cefepime in a one-compartment in vitro infection model.
#P1538 — Efficacy of cefepime / VNRX-5133, a novel broad-spectrum beta-lactamase inhibitor, in a murine bacteremia infection model with carbapenem-resistant Enterobacteriaceae (CREs).
#P1539 — In vitro activity of cefepime alone and in combination with the broad-spectrum beta-lactamase inhibitor VNRX-5133 against ESBL and carbapenamases harbouring Enterobacteriaceae and Pseudomonas spp.
#P1540 | VNRX-5133, a novel broad-spectrum beta-lactamase inhibitor, enhances the activity of cefepime against Enterobacteriaceae and P. aeruginosa isolates in a neutropenic mousethigh infection model.
#P1541 | Susceptibility to cefepime / VNRX-5133 in 298 carbapenem-resistant Enterobacteriaceae producing serine- and metallo-beta-lactamases.
#P1542 | In vitro activity of cefepime in combination with VNRX-5133 against meropenem and/or cefepime resistant clinical isolates of Pseudomonas aeruginosa.
#P1543 | Antimicrobial activity of cefepime in combination with VNRX-5133 against a global collection of clinical isolates.
#P1544 | In vitro activity of cefepime in combination with VNRX-5133 when tested against cephalosporin and carbapenem resistant beta-lactamase producing gram-negative isolates.